Evelo Biosciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Evelo Biosciences generated cash of -$101,235,000, which is less than the previous year. Cash used in financing activities reached the amount of $81,655,000 last year. Net change in cash is therefore -$20,656,000.
Cash Flow
| 2016 | -12.31M | 9.26M | 15.74M |
|---|---|---|---|
| 2017 | -23.26M | -1.74M | 48.96M |
| 2018 | -47.27M | -60.12M | 162.01M |
| 2019 | -71.98M | 51.97M | 4.99M |
| 2020 | -73.06M | -1.31M | 65.46M |
| 2021 | -96.72M | -1.48M | 97.54M |
| 2022 | -101.23M | -622K | 81.65M |
EVLO Cash Flow Statement (2016 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 69.75M | 70.42M | 79.33M | 94.35M | 39.74M | 15.78M | 3.09M |
Operating activities | |||||||
Net income | -114.52M | -122.17M | -93.66M | -85.47M | -56.94M | -28.04M | -13.33M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 2.06M | 2.21M | 2.02M | 1.76M | 1.93M | 834K | 495K |
Stock-based compensation expense | 15.15M | 15.84M | 8.46M | 8.16M | 0 | 1.54M | 419K |
| Deferred income tax benefit | 15.15M | 15.84M | 8.46M | 8.16M | 0 | 1.54M | 419K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 170K | 159K | 837K | -585K | -221K | 774K | -43K |
Cash generated by operating activities | -101.23M | -96.72M | -73.06M | -71.98M | -47.27M | -23.26M | -12.31M |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | -136.08M | 0 | 0 |
Investments In Property Plant And Equipment | -622K | -1.51M | -1.32M | -3.03M | -5.46M | -1.74M | -1.25M |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 10.48M |
Cash generated by investing activities | -622K | -1.48M | -1.31M | 51.97M | -60.12M | -1.74M | 9.26M |
Financing activities | |||||||
Common Stock Issued | 84.54M | 81.75M | 54.99M | 0 | 75.82M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -3.12M | -14.77M | -10M | 4.48M | 0 | 0 | -4M |
Cash used in financing activities | 81.65M | 97.54M | 65.46M | 4.99M | 162.01M | 48.96M | 15.74M |
Net Change In Cash | -20.65M | -666K | -8.91M | -15.01M | 54.60M | 23.96M | 12.69M |
Cash at end of period | 49.09M | 69.75M | 70.42M | 79.33M | 94.35M | 39.74M | 15.78M |
| Data source | Data source | Data source | Data source | Data source |